Abstract

Vascular endothelial growth factor (VEGF) has long been connected to the development of tissue lesion following ischemic stroke. Contradictory findings either situate VEGF as a promoter of large infarct volumes or as a potential attenuator of damage due to its well documented neuroprotective capability. The core of this discrepancy mostly lies on the substantial number of pleiotropic functions driven by VEGF. Mechanistically, these effects are activated through several VEGF receptors for which various closely related ligands exist. Here, we tested in an experimental model of stroke how the differential activation of VEGF receptors 1 and 2 would modify functional and histological outcomes in the acute phase post-ischemia. We also assessed whether VEGF-mediated responses would involve the modulation of inflammatory mechanisms and how this trophic factor acted specifically on neuronal receptors. We produced ischemic infarcts in adult rats by transiently occluding the middle cerebral artery and induced the pharmacological inhibition of VEGF receptors by i.c.v. administration of the specific VEGFR2 inhibitor SU1498 and the pan-VEGFR blocker Axitinib. We evaluated the neurological performance of animals at 24 h following stroke and the occurrence of brain infarctions analyzed at the gross metabolic and neuronal viability levels. We also assessed the induction of peripheral pro- and anti-inflammatory cytokines in the cerebrospinal fluid and blood and assessed the polarization of activated microglia. Finally, we studied the direct involvement of cortical neuronal receptors for VEGF with in vitro assays of excitotoxic damage. Preferential VEGFR1 activation by the endogenous ligand promotes neuronal protection and prevents the presentation of large volume infarcts that highly correlate with neurological performance, while the concomitant activation of VEGFR2 reduces this effect, even in the presence of exogenous ligand. This process partially involves the polarization of microglia to the state M2. At the cellular level, neurons also responded better to the preferential activation of VEGFR1 when challenged to N-methyl-D-aspartate-induced excitotoxicity. Endogenous activation of VEGFR2 hinders the neuroprotective mechanisms mediated by the activation of VEGFR1. The selective modulation of these concurrent processes might enable the development of therapeutic approaches that target specific VEGFR1-mediated signaling during the acute phase post-stroke.

Highlights

  • The neuroprotective molecular mechanisms that drive endogenous adaptive responses to injury in the central nervous system (CNS) are mostly unknown, and their elucidation would ideally open new avenues for rehabilitation

  • VEGFR2 Activation Hinders VEGFR1-Driven Neuroprotection Elicited by Endogenous Ligand in the Acute Phase Post-stroke. It has been known for a long time that vascular endothelial growth factor A (VEGF) synthesis is upregulated by ischemia immediately after an experimental stroke (Hayashi et al, 1997; Plate et al, 1999; Hai et al, 2003), and this phenomenon has been reported to occur in human patients (Issa et al, 1999)

  • Co-administration of VEGFR2 antagonist together with a bolus of 50 ng exogenous agonist resulted in a noticeable improvement in neurological function as compared to animals that received vehicle alone and to the group that was administered with VEGF, which displayed better recoveries (Figures 2A, 3) – pointing to a VEGFR2-independent effect driven by the endogenous ligand

Read more

Summary

Introduction

The neuroprotective molecular mechanisms that drive endogenous adaptive responses to injury in the central nervous system (CNS) are mostly unknown, and their elucidation would ideally open new avenues for rehabilitation. VEGF is responsible for some damaging processes, such as cerebral edema and exacerbated blood-brain barrier leakage (Eliceiri et al, 1999; van Bruggen et al, 1999; Paul et al, 2001; Weis and Cheresh, 2005; Kim et al, 2018; Wu et al, 2018). Such opposing findings have, far, impeded the utilization of VEGF in a clinical setting aimed at alleviating the sequels of ischemic stroke. VEGFR1 is preferably activated by other members of the VEGF family, such as VEGF-B (Olsson et al, 2006)

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.